Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

NCT01862367 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01862367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01862367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
May 17, 2013
Completion date
June 26, 2019
Enrollment
30 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, congenital fxiii deficiency